Treatment News : HIV Drug Selzentry Shows Breast Cancer Treatment Potential

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » June 2012

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


June 13, 2012

HIV Drug Selzentry Shows Breast Cancer Treatment Potential

Drugs that block the CCR5 receptor on cells—such as HIV med Selzentry (maraviroc)—may also help prevent aggressive breast cancers from spreading and causing lethal disease, according to new research conducted at Kimmel Cancer Center of Thomas Jefferson University in Philadelphia and published in a recent issue of Cancer Research.

“These results are dramatic,” said Kimmel researcher and lead author Richard Pestell, MD, PhD, in an accompanying news announcement. “[They] suggest it may prove to be a viable adjuvant therapy to reduce the risk of metastasis in the basal breast cancer subtype.”

CCR5 is found on immune system cells, including CD4 cells. While the exact role of CCR5 in normal immune function isn’t entirely understood, it is believed to play a role in sparking the immune system’s helpful—and potentially harmful—inflammatory response to infections.

CCR5 is a receptor for at least three chemical messengers, or chemokines, in the body, one of which is called CCL5 (or RANTES). HIV research, conducted about 20 years ago, found that CCL5-occupied CCR5 receptors slowed HIV infection of CD4 cells, a discovery that helped lead to the development of Selzentry. More recently, scientists have been focusing on the interaction between CCL5 and CCR5 as it relates to certain cancers.

The research conducted by Pestell and his colleagues helps confirm that CCR5 is found on the cells of basal breast tumors—cancerous growths that do not express androgen or estrogen receptors or the HER-2 protein and are generally difficult to manage—and that CCL5 prompts the cancerous cells to spread to other tissues in the body. And according test tube and rodent studies conducted by the researchers, Selzentry is one CCR5 antagonist that may potentially block the process, including the spread of basal cancer cells to the lungs.

“Our preclinical studies provide the rational basis for studying the use of CCR5 antagonists as new treatments to block the dissemination of basal breast cancers,” Pestell said.

These findings, the researchers added, may also have implications for other cancers where CCR5 promotes metastasis, such as prostate and gastric cancers.

Search: hiv, selzentry, maraviroc, breast cancer, basal cell, ccr5, ccl5, rantes

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.